詳細

源　周治 （ミナモト　シュウジ）

  • 医学科　医学部助教Ａ
Last Updated :2024/04/19

研究者情報

学位

  • 学士（医学）2012年3月

ホームページURL

J-Global ID

研究分野

  • ライフサイエンス / 血液、腫瘍内科学

経歴

  • - 現在  近畿大学医学部血液・膠原病内科助教

学歴

  • - 現在   近畿大学   医学部

所属学協会

  • 日本造血細胞移植学会   日本血液学会   日本内科学会   

研究活動情報

論文

  • Takahiro Haeno; Shinya Rai; Yoshiaki Miyake; Maiko Inoue; Ko Fujimoto; Aki Fujii; Yoshio Iwata; Shuji Minamoto; Takahide Taniguchi; Hiroaki Kakutani; Hiroaki Inoue; Takahiro Kumode; Kentaro Serizawa; Yasuhiro Taniguchi; Chikara Hirase; Yasuyoshi Morita; Hirokazu Tanaka; Yoichi Tatsumi; Takashi Ashida; Itaru Matsumura
    Journal of clinical and experimental hematopathology : JCEH 63 2 99 - 107 2023年06月 
    We retrospectively evaluated long-term outcomes of high dose chemotherapy followed by autologous stem cell transplant (HDC/ASCT) in patients with diffuse large B-cell lymphoma (DLBCL). Between 2004 and 2020, 46 DLBCL patients received HDC/ASCT in our institution, including 12 patients (26.1%), who received as an upfront setting (UFS). At a median follow-up time of 69 months (range, 2-169 months), the 5-year progression-free survival (PFS) rates were 82.5% (95%CI, 46.1-95.3%) in the UFS, and 57.8% (95%CI, 38.1-73.2%) in the relapsed or refractory (R/R) patients (n=34), respectively. The 5-year PFS rates were 62.3% (95%CI, 34.0-81.3%) in primary resistant (n=13) or early relapsing (within 1 year from the initial diagnosis) patients (n=4), and 53.3% (95%CI, 25.9-74.6%) in those relapsing >1 year after the initial diagnosis (n=17), with no statistically significant difference (p=0.498). In R/R patients, multivariate analysis showed that the remission status before HDC/ASCT was an independent poor prognostic factor for progression-free survival (hazard ratio [HR], 17.0; 95%CI, 3.35-86.6; p=0.000630) and high-risk category in the international prognostic index for OS (HR, 9.39; 95%CI, 1.71-51.6; p=0.0100). The incidence of non-relapse mortality by 5 years, and 10 years were 12.2%, and 15.2%, respectively. Eleven patients (23.9%) developed second malignancies, which was the most frequent late complication after HDC/ASCT, with 5-year, and 10-year cumulative incidence of 16.9%, 22.5%, respectively. In conclusion, HDC/ASCT is effective for chemo-sensitive R/R DLBCL regardless of the timing and lines of therapy. However, careful observation is required, considering the long-term complications such as secondary malignancies.
  • Risk factor of oral mucositis after allogeneic hematopoietic stem cell transplantation using FLU/BU(和訳中)
    鳥畑 さやか; 江原 裕基; 助臺 美帆; 下出 孟史; 岩崎 早苗; 李 篤史; 川口 美紅; 木下 優子; 渡瀬 遂生; 濱田 傑; 金澤 仁美; 兵頭 咲紀; 宮本 あかね; 波江野 高大; 角谷 宏明; 源 周治; 口分田 貴裕; 芹澤 憲太郎; 谷口 康博; 森田 泰慶; 榎本 明史; 芦田 隆司
    日本血液学会学術集会 83回 PS - 4 2021年09月
  • CMML様の病型移行を来したMDSに対してアザシチジンが有効であった1例
    角谷 宏明; 口分田 貴裕; 源 周治; 頼 晋也; 森田 泰慶; 田中 宏和; 芦田 隆司; 松村 到
    臨床血液 62 3 205 - 205 (一社)日本血液学会-東京事務局 2021年03月
  • Hiroaki Inoue; Shinya Rai; Hirokazu Tanaka; J Luis Espinoza; Maiko Komori-Inoue; Hiroaki Kakutani; Shuji Minamoto; Takahiro Kumode; Shoko Nakayama; Yasuhiro Taniguchi; Yasuyoshi Morita; Takeshi Okuda; Yoichi Tatsumi; Takashi Ashida; Itaru Matsumura
    Viruses 12 4 2020年04月 [査読有り]
     
    Aplastic anemia is a rare blood disease characterized by the destruction of the hematopoietic stem cells (HSC) in the bone marrow that, in the majority of cases, is caused by an autoimmune reaction. Patients with aplastic anemia are treated with immunosuppressive drugs and some of them, especially younger individuals with a donor available, can be successfully treated with hematopoietic stem cell transplantation (HSCT). We report here a rare case of post-transplant lymphoproliferative disorder (PTLD) associated with Epstein-Barr virus (EBV) reactivation in a 30-year-old female patient who underwent allogeneic HSCT for severe aplastic anemia. The PTLD, which was diagnosed 230 days after transplantation, was localized exclusively in the central nervous system (specifically in the choroid plexus) and manifested with obvious signs of intracranial hypertension. After receiving three cycles of high dose methotrexate (HD-MTX) combined with rituximab, the patient achieved a complete clinical recovery with normalization of blood cell counts, no evidence of EBV reactivation, and no associated neurotoxicity.
  • Takahiro Kumode; Shinya Rai; Hirokazu Tanaka; J Luis Espinoza; Hiroaki Kakutani; Yosaku Watatani; Shuji Minamoto; Yasuhiro Taniguchi; Shoko Nakayama; Yasuyoshi Morita; Takashi Ashida; Itaru Matsumura
    Leukemia research reports 14 100219 - 100219 2020年 
    We report a case with extramedullary tumors affecting the supraclavicular region that presented as a relapse of acute myeloid leukemia (AML) with FLT3-ITD mutation after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Treatment with gilteritinib resulted in remarkable response with disappearance of both the medullary and extramedullary tumors. Subsequently, a 2nd allo-HSCT was performed in an attempt to cure his AML and complete molecular response has been sustained with gilteritinib resumption without worsening GVHD. Targeted therapy with gilteritinib for medullary and extramedullary relapse of FLT3-ITD AML could be effective and suitable as a bridging therapy for allo-HSCT.
  • 芦田 隆司; 小森 舞子; 源 周治; 大山 泰世; 井上 宏昭; 口分田 貴裕; 谷口 康博; 頼 晋也; 森田 泰慶; 地守 慶亮; 前田 朋子; 中野 勝彦; 福島 靖幸; 川野 亜美; 井手 大輔; 前田 岳宏; 椿本 祐子; 藤田 往子; 金光 靖; 松村 到
    日本輸血細胞治療学会誌 65 2 471 - 471 (一社)日本輸血・細胞治療学会 2019年04月
  • 末梢血幹細胞採取前のCD34細胞数測定の有用性
    山田 枝里佳; 斉藤 花往里; 藤本 昂; 角谷 宏明; 岩田 吉生; 谷口 貴英; 源 周治; 大山 泰世; 口分田 貴裕; 井上 宏昭; 芹澤 憲太郎; 谷口 康博; 頼 晋也; 平瀬 主税; 森田 泰慶; 田中 宏和; 岡野 意浩; 坂田 尚己; 芦田 隆司; 松村 到
    日本アフェレシス学会雑誌 37 Suppl. 131 - 131 (一社)日本アフェレシス学会 2018年10月

講演・口頭発表等

MISC

その他のリンク

researchmap


Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.